PMID- 30203710
OWN - NLM
STAT- MEDLINE
DCOM- 20190208
LR  - 20201229
IS  - 1536-0121 (Electronic)
IS  - 1535-3508 (Print)
IS  - 1535-3508 (Linking)
VI  - 17
DP  - 2018 Jan-Dec
TI  - The Molecular Imaging of Natural Killer Cells.
PG  - 1536012118794816
LID - 10.1177/1536012118794816 [doi]
LID - 1536012118794816
AB  - The recent success of autologous T cell-based therapies in hematological 
      malignancies has spurred interest in applying similar immunotherapy strategies to 
      the treatment of solid tumors. Identified nearly 4 decades ago, natural killer 
      (NK) cells represent an arguably better cell type for immunotherapy development. 
      Natural killer cells are cytotoxic lymphocytes that mediate the direct killing of 
      transformed cells with reduced or absent major histocompatibility complex (MHC) 
      and are the effector cells in antibody-dependent cell-mediated cytotoxicity. 
      Unlike T cells, they do not require human leukocyte antigen (HLA) matching 
      allowing for the adoptive transfer of allogeneic NK cells in the clinic. The 
      development of NK cell-based therapies for solid tumors is complicated by the 
      presence of an immunosuppressive tumor microenvironment that can potentially 
      disarm NK cells rendering them inactive. The molecular imaging of NK cells in 
      vivo will be crucial for the development of new therapies allowing for the 
      immediate assessment of therapeutic response and off-target effects. A number of 
      groups have investigated methods for detecting NK cells by optical, nuclear, and 
      magnetic resonance imaging. In this review, we will provide an overview of the 
      advances made in imaging NK cells in both preclinical and clinical studies.
FAU - Shapovalova, Mariya
AU  - Shapovalova M
AD  - 1 Department of Pharmacology, University of Minnesota Medical School, 
      Minneapolis, MN, USA.
FAU - Pyper, Sean R
AU  - Pyper SR
AD  - 2 Department of Pediatrics, University of Minnesota Medical School, Minneapolis, 
      MN, USA.
FAU - Moriarity, Branden S
AU  - Moriarity BS
AD  - 2 Department of Pediatrics, University of Minnesota Medical School, Minneapolis, 
      MN, USA.
FAU - LeBeau, Aaron M
AU  - LeBeau AM
AD  - 1 Department of Pharmacology, University of Minnesota Medical School, 
      Minneapolis, MN, USA.
LA  - eng
GR  - R21 CA216652/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - England
TA  - Mol Imaging
JT  - Molecular imaging
JID - 101120118
SB  - IM
MH  - Humans
MH  - Intravital Microscopy
MH  - Killer Cells, Natural/*cytology
MH  - Luminescent Measurements
MH  - Magnetic Resonance Imaging
MH  - *Molecular Imaging
PMC - PMC6134484
OTO - NOTNLM
OT  - cancer imaging
OT  - cell tracking
OT  - cellular imaging and trafficking
OT  - molecular imaging of immune cell therapies
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2018/09/12 06:00
MHDA- 2019/02/09 06:00
PMCR- 2018/09/11
CRDT- 2018/09/12 06:00
PHST- 2018/09/12 06:00 [entrez]
PHST- 2018/09/12 06:00 [pubmed]
PHST- 2019/02/09 06:00 [medline]
PHST- 2018/09/11 00:00 [pmc-release]
AID - 10.1177_1536012118794816 [pii]
AID - 10.1177/1536012118794816 [doi]
PST - ppublish
SO  - Mol Imaging. 2018 Jan-Dec;17:1536012118794816. doi: 10.1177/1536012118794816.